Israeli Aesthetic Medicine Company Hallura Secures $7M Series A Funding to Advance Next-Gen Hyaluronic Acid Dermal Fillers

VCBeat (WeChat ID: vcbeat) learned from foreign media reports that on November 11, 2019, local time, the Israeli medical aesthetics company Hallura announced the completion of a $7 million Series A financing round. This round was jointly invested by a group of private investors from the United States, Europe, and Israel, with the majority of the investment coming from leading Israeli plastic surgeons and dermatologists.

The current round of financing will be used to complete Hallura’s ongoing clinical trials and register its proprietary hyaluronic acid (HA) dermal fillers in Europe.

Hallura, established in November 2017, is a medical aesthetics company headquartered in Israel. The company was co-founded by Dr. Stéphane Meunier, Ms. Alona Gellerman, Dr. Per Hedén, and Dr. Shimon Eckhouse. Meanwhile, Hallura is a portfolio company of Alon MedTech Ventures and part of the Israel Innovation Authority (IIA) incubator system.

Currently, Hallura is dedicated to the research and development of next-generation hyaluronic acid (HA) dermal fillers. Leveraging proprietary technology developed from the company’s expertise and clinical experience over the past two years, Hallura’s HA dermal fillers differ from the BDDE-crosslinked HA fillers that have been in use for the last 20 years. Hallura has pioneered a novel cross-linking technology designed to meet the growing demand for natural-looking, soft, and non-invasive aesthetic treatments. Based on an entirely different cross-linking mechanism, this technology preserves and protects the long chains of native HA. Compared with leading products on the market, Hallura’s offerings demonstrate superior safety profiles and greater potential for skin lifting.

Dr. Stéphane Meunier, Co-Founder and CEO of Hallura, stated, “We are very proud of the breakthroughs we have achieved over the past two years. We now have a highly promising HA technology platform, state-of-the-art facilities and equipment, and a highly qualified team. HA fillers represent a significant application of our technology, and we plan to explore other medical application areas in the future.”

Dr. Shimon Eckhouse, Co-founder and Chairman of Hallura, stated, “We are delighted to have completed this financing round, which has brought one of the world’s most distinguished teams of aesthetic physicians into our shareholder base. These funds will help us execute our strategy to position Hallura as the market leader in hyaluronic acid (HA) fillers, thereby capturing the largest segment of the global non-invasive aesthetics market.”

Per Hedén, Co-founder of Hallura, stated, “Today, both physicians and patients are seeking a new dermal filler that can meet the broad demands of the market. I believe Hallura’s new hyaluronic acid (HA) series will disrupt this field, introducing a completely new range of HA fillers as well as transforming how they are manufactured and utilized by clinicians. I am delighted to be part of the Hallura team and to contribute to the re-engineering of HA, which has become the most popular aesthetic solution used by physicians worldwide.”

Alon MedTech Ventures, a venture capital firm headquartered in Jordan, Israel, was established in 2013. It was founded and is owned by its current Chairman, Dr. Shimon Eckhouse. Dr. Eckhouse is an inventor, entrepreneur, and investor in the field of medical devices and medical technology. Alon MedTech Ventures focuses on healthcare companies that possess new technologies and solutions capable of improving global human well-being and quality of life.

(Compiled by Wang Fang)